Clinical TrialMay 5, 2026, 08:47 AM
Xencor's XmAb942 Phase 1 Data Positive; XmAb412 Preclinical Data Strong
AI Summary
Xencor Inc. reported positive final results from its Phase 1 study of XmAb942, a long-acting anti-TL1A antibody for inflammatory bowel disease, presented at Digestive Disease Week 2026. The data supports XmAb942's potential as a best-in-class treatment with a convenient 12-week subcutaneous dosing schedule. Additionally, the company presented strong preclinical characterization data for XmAb412, a novel TL1A x IL23p19 bispecific antibody, which is expected to begin its first-in-human study in Q3 2026. Enrollment for the global Phase 2b XENITH-UC study of XmAb942 is on track for results in 2H 2027.
Key Highlights
- XmAb942 Phase 1 data showed 86% of patients predicted to achieve >99% TL1A inhibition in induction.
- XmAb942 maintenance phase predicted >90% TL1A inhibition in 90% of patients with Q12W SC dosing.
- XmAb942 was well tolerated, with overall TEAEs at 75% (vs. 69% for placebo).
- XmAb942 demonstrated an estimated terminal half-life of 74.1 days, supporting 12-week dosing.
- XmAb412 preclinical data showed robust suppression of TL1A and IL23 inflammatory pathways.
- XmAb412 is predicted to have a human half-life of 60-70 days.
- XmAb412 first-in-human study is expected to begin in Q3 2026.
- XmAb942 Phase 2b XENITH-UC study enrollment is on track for results in 2H 2027.
Price Impact
More from XNCR